Stephen Elledge (Emmanuel Ording, Harvard)

Stephen Elledge's Har­vard lab again proves fruit­ful with the launch of high-through­put an­ti­body start­up

Af­ter work­ing with es­teemed Har­vard pro­fes­sor Stephen Elledge to launch TCR-fo­cused TScan Ther­a­peu­tics three years ago, the Long­wood Fund ap­proached the sci­en­tist last spring about spin­ning out more of his work.

To­geth­er, they launched a Cam­bridge, MA-based start­up in De­cem­ber called Im­muneID, which us­es Elledge’s plat­form to iden­ti­fy and tar­get the an­ti­body in­ter­ac­tions that dri­ve im­mune dis­eases, like se­vere al­ler­gies. And on Wednes­day morn­ing, the com­pa­ny un­veiled a $50 mil­lion Se­ries A round, bring­ing its to­tal raise to over $70 mil­lion.

Christoph West­phal

“Im­muneID’s unique and pow­er­ful im­muno­log­i­cal tar­get iden­ti­fi­ca­tion plat­form un­locks the com­plex­i­ty of hu­man im­mune re­spons­es to guide the de­vel­op­ment of pre­ci­sion im­munol­o­gy ther­a­peu­tics in ar­eas where there re­mains sig­nif­i­cant un­met pa­tient need,” Long­wood’s Christoph West­phal said in a state­ment.

The round was led by Al­ta Part­ners, with a hand from Alexan­dria Ven­ture In­vest­ments, Red­wood Cap­i­tal In­vest­ments, Sec­tion 32, Tekla Cap­i­tal Man­age­ment, Arch Ven­ture Part­ners, the Long­wood Fund, Pi­tan­go Health Tech, In-Q-Tel, Xfund and oth­ers.

While Elledge set out with TScan to screen anti­gen-TCR match­es in a faster, more sys­tem­at­ic way, Im­muneID is look­ing at an­ti­body tar­gets. The plat­form is based on tech de­vel­oped along with Johns Hop­kins’ Ben Lar­man and Har­vard’s Tomasz Ku­la, and us­es next-gen se­quenc­ing, ro­bot­ic au­toma­tion and AI to “in­ter­ro­gate and ul­ti­mate­ly drug” the im­mune sys­tem. It re­quires small vol­umes of flu­ids (like plas­ma or sali­va), that can be fresh or frozen, pro­vid­ing the com­pa­ny flex­i­bil­i­ty to sur­vey broad pa­tient pop­u­la­tions. And every time the team runs the plat­form, they col­lect a huge amount of da­ta on hun­dreds of thou­sands of an­ti­body in­ter­ac­tions.

David Don­abe­di­an

“So you can imag­ine what you find are an­ti­bod­ies against virus­es if that’s what you’re in­ter­est­ed in; you find IgE an­ti­bod­ies against al­ler­gens that could cause ana­phy­lax­is, you find au­toan­ti­bod­ies that might be mark­ers of au­toim­mune dis­ease, can­cer, etc.,” said Lea Hachi­gian, who was CEO be­fore David Don­abe­di­an took the helm in April.

The com­pa­ny plans on de­vel­op­ing its own, in-house pipeline of next-gen pre­ci­sion ther­a­pies, though Don­abe­di­an says the team will “re­main open to oth­er busi­ness de­vel­op­ment op­por­tu­ni­ties as they arise.” He de­clined to com­ment on a time­line for reach­ing the clin­ic.

“Though we can’t pro­vide more de­tail at this time, we have en­gaged in promis­ing con­ver­sa­tions with po­ten­tial biotech and phar­ma part­ners,” he said via email.

While Hachi­gian told End­points News in Feb­ru­ary that al­ler­gies will be the team’s main fo­cus to start, Don­abe­di­an says the com­pa­ny is al­so con­tin­u­ing its work on oth­er ar­eas of fo­cus, in­clud­ing au­toim­mune dis­eases, can­cer and in­fec­tious dis­eases.

No­var­tis reshuf­fles its wild cards; Tough sell for Bio­gen? Googling pro­teins; Ken Fra­zier's new gig; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

If you enjoy the People section in this report, you may also want to check out Peer Review, my colleagues Alex Hoffman and Kathy Wong’s comprehensive compilation of comings and goings in biopharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

Demis Hassabis, DeepMind CEO (Qianlong/Imaginechina via AP Images)

Google's Deep­Mind opens its pro­tein data­base to sci­ence — po­ten­tial­ly crack­ing drug R&D wide open

Nearly a year ago, Google’s AI outfit DeepMind announced they had cracked one of the oldest problems in biology: predicting a protein’s structure from its sequence alone. Now they’ve turned that software on nearly every human protein and hundreds of thousands of additional proteins from organisms important to medical research, such as fruit flies, mice and malaria parasite.

The new database of roughly 350,000 protein sequences and structures represents a potentially monumental achievement for the life sciences, one that could hasten new biological insights and the development of new drugs. DeepMind said it will be free and accessible to all researchers and companies.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

In­side Bio­gen's scram­ble to sell Aduhelm: Pro­ject 'Javelin' and pres­sure to ID as many pa­tients as pos­si­ble

In anticipation of Aduhelm’s approval for Alzheimer’s in June, Biogen employees were directed to identify and guarantee treatment centers would administer the drug through a program called “Javelin,” a senior Biogen employee told Endpoints News.

The program identified about 800 centers for use, he said, and Biogen now pays for the use of bioassays to identify beta amyloid in potential patients having undergone a lumbar puncture procedure, the employee said — and one center preparing to administer the drug confirmed its participation in the bioassay program.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

No­var­tis dis­cards one of its ‘wild card’ drugs af­ter it flops in key study. But it takes one more for the hand

Always remember just how risky it is to gamble big on small studies.

A little more than 4 years ago, Novartis reportedly put up a package worth up to $1 billion for the dry eye drug ECF843 after a small biotech called Lubris put it through its paces in a tiny study of 40 moderate to severe patients, tracking some statistically significant markers of efficacy.

By last fall, the program had risen up to become one of CEO Vas Narasimhan’s top “wild card” programs in line for a potential breakthrough year in 2021. These drugs were all considered high-risk, high-reward efforts. And in this case, risk won.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Three biotechs price hefty IPOs just be­fore the week­end, while a fourth and a SPAC seek spots on Wall Street

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.

A handful of biotechs are hitting Wall Street just before the start of the weekend, with three companies — Caribou Biosciences, Sophia Genetics and Absci — all pricing big raises Wednesday and Thursday. Gamma delta T cell-focused IN8bio relaunched its IPO campaign months after postponing it last November, seeking a slightly lower raise. And another SPAC has filed for a public debut.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

Victor Perlroth, Kodiak Sciences CEO

Ko­di­ak turns down $125M pay­ment from Bak­er Bros. deal, slash­es roy­al­ty cap by 55%

Following a massive public raise last November, Kodiak Sciences has re-worked a royalty sale agreement with an old partner — and declined new funds in the process.

Kodiak is turning down a planned $125 million payment from Baker Bros. Advisors, according to an SEC filing, cutting short an agreement that saw the biotech hand over a 4.5% stream of royalty sales on its experimental anti-VEGF therapy KSI-301 for retinal vascular diseases. In conjunction with the move, Kodiak is shrinking the royalty cap from just over $1 billion to $450 million.

EMA re­jects FDA-ap­proved Parkin­son's drug, signs off on Mod­er­na vac­cine use in ado­les­cents ahead of FDA

The European Medicines Agency on Friday rejected Kyowa Kirin’s Parkinson’s disease drug Nouryant (istradefylline), which the US FDA approved in 2019 under the brand name Nourianz.

EMA said it considered that the results of the clinical studies used to support the application “were inconsistent and did not satisfactorily show that Nouryant was effective at reducing the ‘off’ time. Only four out of the eight studies showed a reduction in ‘off’ time, and the effect did not increase with an increased dose of Nouryant.”

6 top drug­mak­ers of­fer per­spec­tives on FDA's new co­vari­ates in RCTs guid­ance

Back in May, the FDA revised and expanded a 2019 draft guidance that spells out how to adjust for covariates in the statistical analysis of randomized controlled trials.

Building on the ICH’s E9 guideline on the statistical principles for clinical trials, the 3-page draft was transformed into an 8-page draft, with more detailed recommendations on linear and nonlinear models to analyze the efficacy endpoints in RCTs.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Mol­e­c­u­lar Di­ag­nos­tics Can Trans­form Can­cer Care. Let’s Make It Hap­pen.

Like so many people around the world, my life has been profoundly shaped by cancer. Those personal experiences, along with a deep love of clinical laboratory science and a passion to apply the power of genomics in medicine, motivated me to launch a company that would improve cancer care through better diagnostics. Thirteen years later, I am proud that we are delivering more accurate information at multiple points along the patient journey, with a focus on eight of the 10 cancers that are most commonly diagnosed in the United States.